In Vitro and In Vivo Assessment of Darolutamide Encapsulated Lipid-Extruded PEGylated Liposomal Formulation.
Pardhi E, Khemchandani R, Pawar A, Patil R, Samanthula G, Mehra NK.
ACS Appl Bio Mater · journal article · DOI 10.1021/acsabm.5c02537 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för darolutamide. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
23 träffarVigilance for drug safety of darolutamide in the cancer therapies: a disproportionality analysis from the FDA Adverse Event Reporting System.
Wu Z, Liang Y, Li S, Chen J.
Naunyn Schmiedebergs Arch Pharmacol · journal article · DOI 10.1007/s00210-026-05253-5ARAMON, a phase 2 open-label trial of darolutamide monotherapy in patients with biochemical recurrence or oligometastatic castration-sensitive prostate cancer after radical prostatectomy or primary radiotherapy.
Laccetti AL, Smith MR, Scher HI, Nowfar S, Einstein D, Martin B, Adorjan P, Dissanayake M, Verholen F, Gao X.
Eur Urol Focus · journal article · DOI 10.1016/j.euf.2026.02.005WOMBAT (ANZUP 2201): A Phase 2, Single-arm Study of Bipolar Androgen Therapy in Patients with Nonmetastatic Castration-resistant Prostate Cancer with Prostate-specific Antigen Progression on Darolutamide.
Talmor B, Harris CA, Gianacas C, Pook D, Tan TH, Davis ID, Krieger L, Marx G, Anton A, Sharma S, Goh JC, Xu K, Pranavan G, Dhillon HM, Antonarakis ES, Denmeade SR, Horvath L, Oakes SR, Allen R, Fontela A, Reich E, Crumbaker M, Hurwitz J, Joshua AM.
Eur Urol Oncol · clinical trial, phase ii; multicenter study; journal article · DOI 10.1016/j.euo.2026.02.004Progression-free survival with darolutamide and docetaxel vs. androgen receptor pathway inhibitors vs. docetaxel in metastatic hormone-sensitive prostate cancer: A real-world multicenter retrospective study.
Rinderknecht E, Bielstein G, Cathomas R, Schlack K, Bastian JLD, Darr C, Unland-Gies D, Kappler P, Paffenholz P, Richter J, Müller M, Seitz AK, Steinestel J, Heidegger I, Burger M, Breyer J, Schnabel MJ.
Urol Oncol · comparative study; multicenter study; journal article · DOI 10.1016/j.urolonc.2026.111028Treatment patterns in patients with castration-resistant prostate cancer who received darolutamide in the ARAMIS trial in Spain: PARASEC study.
Puente J, Campanario R, Marmolejo D, Cantero-Mellado JA, Gómez-Ferrer Á, Rodríguez Antolín A, Ribal MJ, Picola Brau N, Ledo MJ, Hernandez C, Llorente C, González-Enguita C, Bisonó Castillo Á, Benejam J, Gil Guijarro J, Garcia-Sanchez J, Folqué J, Casas-Nebra J.
Clin Transl Oncol · research-article; multicenter study; journal article; observational study · DOI 10.1007/s12094-026-04233-8[Darolutamide plus androgene-deprivation therapy in hormone-sensitive metastatic prostate cancer].
Grassi P, Benderra MA.
Bull Cancer · letter · DOI 10.1016/j.bulcan.2025.11.015Patient selection for triplet therapy with darolutamide in metastatic castration-sensitive prostate cancer and patterns of administration: a Spanish multicenter study.
Alonso-Gordoa T, Fernández-Calvo O, García-Carbonero I, Álvarez-Rodríguez S, Sánchez-Escribano R, Anguera G, González-Del-Alba A, Gallardo E, Cacho D, Vidal N, Pinto Á, Perezagua C, Zafra-Poves M, Cassinello J, Rodriguez-Vida A, López-Campos F, Vázquez-Estévez S.
Clin Transl Oncol · multicenter study; journal article · DOI 10.1007/s12094-025-04174-8Effects of Prior Local Therapy by Radical Prostatectomy or Radiotherapy on the Efficacy and Quality of Life of Patients Treated With Darolutamide in ARAMIS.
Saar M, Fizazi K, Shore ND, Smith M, Damber JE, Semenov A, Ribal MJ, Birtle A, Rigaud J, Wallis CJD, Grimm MO, Halabi S, Armstrong AJ, Mohamed AF, Adorjan P, Srinivasan S, Verholen F, Morgans AK, Siemens DR.
Cancer Med · research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1002/cam4.71343Synergistic Efficacy of Gedatolisib and Darolutamide in Prostate Cancer to Overcome Resistance to Androgen-Targeted Therapy.
Khan S, Molden J, Iversrud C, Mattonen D, Rossetti S, Laing L.
Int J Mol Sci · research-article; journal article · DOI 10.3390/ijms262411810Integration of Darolutamide in the Treatment Landscape for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis of Efficacy and Safety.
Melchior F, Koett M, Keller F, Artamonova N, Giannini G, Kafka M, Ladurner M, Neuwirt H, Bektic J, Horninger W, Heidegger I.
Eur Urol Open Sci · research-article; journal article · DOI 10.1016/j.euros.2025.11.011Darolutamide-based triple therapy combined with PSMA imaging guided focal treatment in patients with prostate cancer: a multicenter retrospective study.
Zhong D, Zhang R, Wu J, Guo Z, Zhang Y, Zhou Q, Zou Z, Lin D, Lu Z, Wang J, Wu J, Ye L, Wei Y.
Front Pharmacol · research-article; journal article · DOI 10.3389/fphar.2025.1692407An Eco-Friendly and Quality-by-Design Optimized Synchronous Spectrofluorescence Method for the Simultaneous Determination of Cleaning Residues of Anticancer Drugs Darolutamide and Enzalutamide From Manufacturing Surfaces.
Jain JK, Sujatha K, Sheelarani T, Trivedi H, Khemchandani R, Gananadhamu S.
Luminescence · journal article · DOI 10.1002/bio.70376Darolutamide (Nubeqa): Therapeutic area: Metastatic castration-sensitive prostate cancer: Reimbursement Review
Författaruppgift saknas
Tidskrift saknas · reviewSafety and efficacy of darolutamide in combination with androgen-deprivation therapy for prostate cancer: a systematic review and meta-analysis.
Khan A, Akhter HAR, Rath S, Aslam R, Salamon I, Ali MA, Bashir M, Antar M, Muhibullah F.
Ann Med Surg (Lond) · research-article; journal article · DOI 10.1097/ms9.0000000000004029Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer
Författaruppgift saknas
Tidskrift saknas · reviewDarolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP).
Morgans AK, Chehrazi-Raffle A, Niazi T, Shore ND, Ross AE, Røder A, Gomes AJ, Supiot S, Barthélémy P, Hatano K, Ruiz CBC, Yoshida S, Herrera-Imbroda B, Gratton M, Gschwend JE, Hope TA, Joensuu H, Kuss I, Le Berre MA, Dimova-Dobreva M, Fizazi K.
Future Oncol · clinical trial protocol; methods-article; journal article · DOI 10.1080/14796694.2025.2577633Assessing the efficacy of darolutamide in metastatic hormone-sensitive prostate cancer based on subgroup meta-analysis and reconstructed individual patient data.
Zhang F, Luo Z, Xue Q, Guo X, Fu Q, Zhang W, Xiong Y, Alisha PA, Okoli UA, Zhang G, Jiao Y.
Discov Oncol · research-article; journal article · DOI 10.1007/s12672-025-03875-4Darolutamide (Nubeqa): Indication: In combination with androgen deprivation therapy for the treatment of metastatic castration-sensitive prostate cancer: Reimbursement Recommendation
Författaruppgift saknas
Tidskrift saknas · reviewDiscovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies.
Moilanen AM, Riikonen R, Oksala R, Ravanti L, Aho E, Wohlfahrt G, Nykänen PS, Törmäkangas OP, Palvimo JJ, Kallio PJ.
Sci Rep · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/srep12007ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer.
Fizazi K, Albiges L, Loriot Y, Massard C.
Expert Rev Anticancer Ther · other; review; journal article · DOI 10.1586/14737140.2015.1081566ODM-201 is safe and active in metastatic castration-resistant prostate cancer.
Författaruppgift saknas
Cancer Discov · comment; journal article · DOI 10.1158/2159-8290.cd-rw2014-150Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.
Fizazi K, Massard C, Bono P, Jones R, Kataja V, James N, Garcia JA, Protheroe A, Tammela TL, Elliott T, Mattila L, Aspegren J, Vuorela A, Langmuir P, Mustonen M, ARADES study group.
Lancet Oncol · clinical trial, phase ii; comparative study; research support, non-u.s. gov't; multicenter study; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1016/s1470-2045(14)70240-2